New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCerebrolysin vs Adipotide

Cerebrolysin vs Adipotide

Side-by-side comparison of key properties, dosing, and research.

Cognitive EnhancementAnti-Aging & Longevity
Cerebrolysin
Fat Loss & Metabolic
Adipotide
Summary
Cerebrolysin is a porcine brain-derived neuropeptide complex that mimics the action of endogenous neurotrophic factors (BDNF, NGF, GDNF, NT-3). It promotes neurogenesis, neuroprotection, and synaptic plasticity, and is approved in many countries for stroke, traumatic brain injury, and Alzheimer's disease.
Adipotide (FTPP) is a chimeric proapoptotic peptide that selectively targets and destroys blood vessels feeding white adipose tissue. It binds prohibitin on the vasculature of fat tissue, delivering a proapoptotic sequence that induces cell death in fat-specific blood vessels, causing targeted fat tissue regression.
Half-Life
Variable for the complex; individual peptide fractions: minutes to hours
Estimated 2-4 hours
Admin Route
IV, IM
Subcutaneous, Intravenous (research)
Research
Typical Dose
5–10 mL
Not established for humans; primate studies used 0.1-1 mg/kg
Frequency
Daily for 10–20 days
Daily for 4 weeks (research protocol)
Key Benefits
  • Promotes neurogenesis and synaptic plasticity
  • Approved for stroke rehabilitation (accelerates recovery)
  • Alzheimer's disease: slows progression and improves cognition
  • Traumatic brain injury recovery
  • Enhances memory and executive function
  • Neuroprotection against oxidative stress and excitotoxicity
  • Anti-amyloid and anti-tau effects
  • Mood improvement and reduced anxiety
  • Targeted reduction of white adipose tissue
  • Promotes fat vasculature apoptosis without systemic toxicity
  • Demonstrated significant fat loss in primate studies
  • Potential for visceral and subcutaneous fat reduction
  • Novel non-hormonal mechanism distinct from GLP-1 agonists
  • Explored for obesity and metabolic syndrome
Side Effects
  • Generally well tolerated
  • Mild nausea and dizziness (IV infusion)
  • Headache at initiation
  • Rare: agitation (usually at very high doses)
  • +2 more
  • Renal toxicity observed in primate studies (transient, dose-dependent)
  • Dehydration and electrolyte imbalances in research
  • Weight regain upon cessation
  • Limited human data; side effect profile largely from animal studies
Stacks With